CD274 and neoplasm: The Tumor Immunity in the MicroEnvironment (TIME) scale, which categorizes tumors according to PD-L1 and tumor-infiltrating lymphocyte (TIL) positivity, has been implemented to predict responses to immunotherapy in several types of tumors (107).